Characterization_NN
of_IN
a_DT
mutant_JJ
cell_NN
line_NN
that_WDT
does_VBZ
not_RB
activate_VB
NF-kappaB_NN
in_IN
response_NN
to_TO
multiple_JJ
stimuli_NNS
._.

Numerous_JJ
genes_NNS
required_VBN
during_IN
the_DT
immune_JJ
or_CC
inflammation_NN
response_NN
as_RB
well_RB
as_IN
the_DT
adhesion_NN
process_NN
are_VBP
regulated_VBN
by_IN
nuclear_JJ
factor_NN
kappaB_NN
-LRB-_-LRB-
NF-kappaB_NN
-RRB-_-RRB-
._.

Associated_VBN
with_IN
its_PRP$
inhibitor_NN
,_,
I_NN
kappaB_NN
,_,
NF-kappaB_NN
resides_VBZ
as_IN
an_DT
inactive_JJ
form_NN
in_IN
the_DT
cytoplasm_NN
._.

Upon_IN
stimulation_NN
by_IN
various_JJ
agents_NNS
,_,
I_NN
kappaB_NN
is_VBZ
proteolyzed_VBN
and_CC
NF-kappaB_NN
translocates_VBZ
to_TO
the_DT
nucleus_NN
,_,
where_WRB
it_PRP
activates_VBZ
its_PRP$
target_NN
genes_NNS
._.

The_DT
transduction_NN
pathways_NNS
that_WDT
lead_VBP
to_TO
I_NN
kappaB_NN
inactivation_NN
remain_VBP
poorly_RB
understood_VBN
._.

In_IN
this_DT
study_NN
,_,
we_PRP
have_VBP
characterized_VBN
a_DT
cellular_JJ
mutant_NN
,_,
the_DT
70\/Z3-derived_JJ
1.3_CD
E2_NN
murine_JJ
pre-B_JJ
cell_NN
line_NN
,_,
that_WDT
does_VBZ
not_RB
activate_VB
NF-kappaB_NN
in_IN
response_NN
to_TO
several_JJ
stimuli_NNS
._.

We_PRP
demonstrate_VBP
that_IN
upon_IN
stimulation_NN
by_IN
lipopolysaccharide_NN
,_,
Taxol_NN
,_,
phorbol_NN
myristate_NN
acetate_NN
,_,
interleukin-1_NN
,_,
or_CC
double-stranded_JJ
RNA_NN
,_,
I_NN
kappaB_NN
alpha_NN
is_VBZ
not_RB
degraded_VBN
,_,
as_IN
a_DT
result_NN
of_IN
an_DT
absence_NN
of_IN
induced_VBN
phosphorylation_NN
on_IN
serines_NNS
32_CD
and_CC
36_CD
._.

Neither_CC
a_DT
mutation_NN
in_IN
I_NN
kappaB_NN
alpha_NN
nor_CC
a_DT
mutation_NN
in_IN
p50_NN
or_CC
relA_NN
,_,
the_DT
two_CD
major_JJ
subunits_NNS
of_IN
NF-kappaB_NN
in_IN
this_DT
cell_NN
line_NN
,_,
accounts_VBZ
for_IN
this_DT
phosphorylation_NN
defect_NN
._.

As_RB
well_RB
as_IN
culminating_VBG
in_IN
the_DT
inducible_JJ
phosphorylation_NN
of_IN
I_NN
kappaB_NN
alpha_NN
on_IN
serines_NNS
32_CD
and_CC
36_CD
,_,
all_PDT
the_DT
stimuli_NNS
that_WDT
are_VBP
inactive_JJ
on_IN
1.3_CD
E2_NN
cells_NNS
exhibit_VBP
a_DT
sensitivity_NN
to_TO
the_DT
antioxidant_JJ
pyrrolidine_NN
dithiocarbamate_NN
-LRB-_-LRB-
PDTC_NN
-RRB-_-RRB-
._.

In_IN
contrast_NN
,_,
stimuli_NNS
such_JJ
as_IN
hyperosmotic_JJ
shock_NN
or_CC
phosphatase_NN
inhibitors_NNS
,_,
which_WDT
use_VBP
PDTC-insensitive_JJ
pathways_NNS
,_,
induce_VBP
I_NN
kappaB_NN
alpha_NN
degradation_NN
in_IN
1.3_CD
E2_NN
._.

Analysis_NN
of_IN
the_DT
redox_NN
status_NN
of_IN
1.3_CD
E2_NN
does_VBZ
not_RB
reveal_VB
any_DT
difference_NN
from_IN
wild-type_JJ
70Z\/3_NN
._.

We_PRP
also_RB
report_VBP
that_IN
the_DT
human_JJ
T-cell_NN
leukemia_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HTLV-1_NN
-RRB-_-RRB-
-_:
derived_VBN
Tax_NN
trans-activator_NN
induces_VBZ
NF-kappaB_NN
activity_NN
in_IN
1.3_CD
E2_NN
,_,
suggesting_VBG
that_IN
this_DT
viral_JJ
protein_NN
does_VBZ
not_RB
operate_VB
via_IN
the_DT
defective_JJ
pathway_NN
._.

Finally_RB
,_,
we_PRP
show_VBP
that_IN
two_CD
other_JJ
I_NN
kappaB_NN
molecules_NNS
,_,
I_NN
kappaB_NN
beta_NN
and_CC
the_DT
recently_RB
identified_VBN
I_NN
kappaB_NN
epsilon_NN
,_,
are_VBP
not_RB
degraded_VBN
in_IN
the_DT
1.3_CD
E2_NN
cell_NN
line_NN
following_VBG
stimulation_NN
._.

Our_PRP$
results_NNS
demonstrate_VBP
that_IN
1.3_CD
E2_NN
is_VBZ
a_DT
cellular_JJ
transduction_NN
mutant_NN
exhibiting_VBG
a_DT
defect_NN
in_IN
a_DT
step_NN
that_WDT
is_VBZ
required_VBN
by_IN
several_JJ
different_JJ
stimuli_NNS
to_TO
activate_VB
NF-kappaB_NN
._.

In_IN
addition_NN
,_,
this_DT
analysis_NN
suggests_VBZ
a_DT
common_JJ
step_NN
in_IN
the_DT
signaling_NN
pathways_NNS
that_WDT
trigger_VBP
I_NN
kappaB_NN
alpha_NN
,_,
I_NN
kappaB_NN
beta_NN
,_,
and_CC
I_NN
kappaB_NN
epsilon_NN
degradation_NN
._.

